Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Can-Fite Biopharma Ltd ADR
(NY:
CANF
)
2.380
+0.140 (+6.25%)
Official Closing Price
Updated: 8:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Can-Fite Biopharma Ltd ADR
< Previous
1
2
3
4
Next >
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
June 02, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
June 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 15, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
May 09, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
May 02, 2023
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Via
MarketBeat
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
May 02, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
April 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
April 10, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
March 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
March 16, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
March 13, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
February 14, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
January 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
January 11, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
January 10, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Announces ADS Ratio Change
December 30, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
December 28, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
December 27, 2022
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.
Via
TheNewswire.com
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
December 08, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
November 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
November 02, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 31, 2022
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Via
TheNewswire.com
Exposures
Product Safety
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
October 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
October 13, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite BioPharma Ltd. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
September 23, 2022
Via
ACCESSWIRE
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
August 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
September 12, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
August 23, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
August 22, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.